| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1029180490 |
| P356 | DOI | 10.1007/S12185-011-0886-8 |
| P698 | PubMed publication ID | 21706145 |
| P2093 | author name string | Shinichiro Okamoto | |
| Mineo Kurokawa | |||
| Yoshiaki Tomiyama | |||
| Keita Kirito | |||
| Kensuke Usuki | |||
| Helen Wei | |||
| Kiyoshi Ando | |||
| Koji Iwato | |||
| Koji Miyazaki | |||
| Richard Lizambri | |||
| Satoshi Hashino | |||
| Shinichiro Mori | |||
| Yuji Yonemura | |||
| Yukari Shirasugi | |||
| P2860 | cites work | International consensus report on the investigation and management of primary immune thrombocytopenia | Q28262094 |
| Effects of pegylated recombinant human megakaryocyte growth and development factor in patients with idiopathic thrombocytopenic purpura | Q33343050 | ||
| Immune thrombocytopenic purpura (ITP) plasma and purified ITP monoclonal autoantibodies inhibit megakaryocytopoiesis in vitro | Q33347325 | ||
| Idiopathic thrombocytopenic purpura and mononeuropathy multiplex | Q33349939 | ||
| Management of immune thrombocytopenic purpura in adults | Q33360299 | ||
| Is eradication therapy useful as the first line of treatment in Helicobacter pylori-positive idiopathic thrombocytopenic purpura? Analysis of 207 eradicated chronic ITP cases in Japan | Q33365392 | ||
| Effect of Helicobacter pylori eradication in patients with chronic idiopathic thrombocytopenic purpura-a randomized controlled trial | Q33366597 | ||
| Cell-mediated lysis of autologous platelets in chronic idiopathic thrombocytopenic purpura | Q33370272 | ||
| AMG 531, a thrombopoiesis-stimulating protein, for chronic ITP. | Q33373031 | ||
| Helicobacter pylori and immune thrombocytopenic purpura: unsolved questions and controversies | Q33373338 | ||
| Recent advances in the treatment of idiopathic thrombocytopenic purpura | Q33375565 | ||
| Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial | Q33378523 | ||
| Safety and efficacy of long-term treatment with romiplostim in thrombocytopenic patients with chronic ITP. | Q33381893 | ||
| Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group | Q33381983 | ||
| Does Helicobacter pylori eradication therapy result in a platelet count improvement in adults with immune thrombocytopenic purpura regardless of H pylori infection? ASH evidence-based review 2008. | Q33382374 | ||
| Long-term efficacy of Helicobacter pylori eradication in patients with idiopathic thrombocytopenic purpura: 7-year follow-up prospective study | Q33382528 | ||
| Epidemiology, pathophysiology, and initial management of chronic immune thrombocytopenic purpura | Q33382754 | ||
| Characteristics of immune thrombocytopenic purpura: a guide for clinical practice | Q33383184 | ||
| Epidemiology of immune thrombocytopenic purpura in the General Practice Research Database | Q33383462 | ||
| The incidence of idiopathic thrombocytopenic purpura among adults: a population-based study and literature review | Q33383464 | ||
| Pathogenesis of chronic immune thrombocytopenia: increased platelet destruction and/or decreased platelet production | Q33384644 | ||
| Platelet count response to H. pylori treatment in patients with immune thrombocytopenic purpura with and without H. pylori infection: a systematic review | Q33384729 | ||
| A phase II, open-label, sequential-cohort, dose-escalation study of romiplostim in Japanese patients with chronic immune thrombocytopenic purpura | Q33385082 | ||
| Evaluation of bone marrow reticulin formation in chronic immune thrombocytopenia patients treated with romiplostim | Q33385762 | ||
| Chronic immune thrombocytopenia in adults: epidemiology and clinical presentation | Q33387156 | ||
| The geoepidemiology of immune thrombocytopenic purpura | Q33387219 | ||
| Assessment of immunogenicity of romiplostim in clinical studies with ITP subjects | Q33388267 | ||
| Management of chronic immune thrombocytopenic purpura: targeting insufficient megakaryopoiesis as a novel therapeutic principle | Q33390001 | ||
| Population Pharmacokinetics of Eltrombopag in Healthy Subjects and Patients With Chronic Idiopathic Thrombocytopenic Purpura | Q33391013 | ||
| Eltrombopag for management of chronic immune thrombocytopenia (RAISE): a 6-month, randomised, phase 3 study | Q33391580 | ||
| Romiplostim or Standard of Care in Patients with Immune Thrombocytopenia | Q33392763 | ||
| Epidemiology of primary immune thrombocytopenia in children and adults in Japan: a population-based study and literature review | Q33394301 | ||
| Long-term observation of 208 adults with chronic idiopathic thrombocytopenic purpura. | Q33489560 | ||
| Therapy for adults with refractory chronic immune thrombocytopenic purpura | Q33498485 | ||
| Racial and ethnic differences in response to medicines: towards individualized pharmaceutical treatment. | Q34980621 | ||
| Racial, ethnic and gender differences in response to medicines | Q40964013 | ||
| Pharmacodynamics and pharmacokinetics of AMG 531, a thrombopoiesis-stimulating peptibody, in healthy Japanese subjects: a randomized, placebo-controlled study. | Q55044849 | ||
| P433 | issue | 1 | |
| P921 | main subject | thrombocytopenia | Q585285 |
| chronic immune thrombocytopenia | Q1088037 | ||
| romiplostim | Q1235195 | ||
| phase III clinical trial | Q42824827 | ||
| P304 | page(s) | 71-80 | |
| P577 | publication date | 2011-06-25 | |
| P1433 | published in | International Journal of Hematology | Q6051416 |
| P1476 | title | Romiplostim for the treatment of chronic immune thrombocytopenia in adult Japanese patients: a double-blind, randomized Phase III clinical trial | |
| P478 | volume | 94 |
| Q91639087 | American Society of Hematology 2019 guidelines for immune thrombocytopenia |
| Q33400911 | An open-label extension study evaluating the safety and efficacy of romiplostim for up to 3.5 years in thrombocytopenic Japanese patients with immune thrombocytopenic purpura (ITP). |
| Q33401956 | Bleeding and mortality outcomes in ITP clinical trials: a review of thrombopoietin mimetics data |
| Q33425012 | Case study of remission in adults with immune thrombocytopenia following cessation of treatment with the thrombopoietin mimetic romiplostim |
| Q33409109 | Cost effectiveness of romiplostim for the treatment of chronic immune thrombocytopenia in Ireland |
| Q26779408 | Current Management of Primary Immune Thrombocytopenia |
| Q33426166 | Effect of a thrombopoietin receptor agonist on use of intravenous immune globulin in patients with immune thrombocytopenia |
| Q33425644 | Efficacy and safety of the thrombopoietin receptor agonist romiplostim in patients aged ≥ 65 years with immune thrombocytopenia |
| Q33437732 | Efficacy and safety of thrombopoietin receptor agonists in patients with primary immune thrombocytopenia: A systematic review and meta-analysis |
| Q55424728 | Eltrombopag versus romiplostim in treatment of adult patients with immune thrombocytopenia: A systematic review incorporating an indirect-comparison meta-analysis. |
| Q53091622 | Ex vivo activation of angiogenic property in human peripheral blood-derived monocytes by thrombopoietin. |
| Q90602246 | Guideline on immune thrombocytopenia in adults: Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular. Project guidelines: Associação Médica Brasileira - 2018 |
| Q33407802 | Immune thrombocytopenia -- what are the new treatment options? |
| Q33416547 | Impact of self-administration of romiplostim by patients with chronic immune thrombocytopenia compared with administration by a healthcare provider |
| Q33424664 | Integrated analysis of long-term safety in patients with chronic immune thrombocytopaenia (ITP) treated with the thrombopoietin (TPO) receptor agonist romiplostim |
| Q26745753 | Long-term safety and efficacy of romiplostim for treatment of immune thrombocytopenia |
| Q33409611 | Long-term safety and tolerability of romiplostim in patients with primary immune thrombocytopenia: a pooled analysis of 13 clinical trials |
| Q64057585 | Optimal use of thrombopoietin receptor agonists in immune thrombocytopenia |
| Q33433662 | Rate of bleeding-related episodes in adult patients with primary immune thrombocytopenia: a retrospective cohort study using a large administrative medical claims database in the US. |
| Q38658259 | Rate of bleeding-related episodes in elderly patients with primary immune thrombocytopenia: a retrospective cohort study |
| Q26741269 | Role of romiplostim in splenectomized and nonsplenectomized patients with immune thrombocytopenia |
| Q99617433 | Romiplostim and Eltrombopag in Immune Thrombocytopenia as a Second-Line Treatment |
| Q33410572 | Romiplostim as early treatment for refractory primary immune thrombocytopenia |
| Q33400560 | Romiplostim for the treatment of primary immune thrombocytopenia |
| Q91821631 | Romiplostim in adult patients with newly diagnosed or persistent immune thrombocytopenia (ITP) for up to 1 year and in those with chronic ITP for more than 1 year: a subgroup analysis of integrated data from completed romiplostim studies |
| Q33399598 | Romiplostim: a review of its use in immune thrombocytopenia |
| Q33441008 | Safety and efficacy of romiplostim in splenectomized and nonsplenectomized patients with primary immune thrombocytopenia |
| Q26826853 | Severe bleeding events in adults and children with primary immune thrombocytopenia: a systematic review |
| Q45058551 | Successful treatment of eltrombopag-resistant refractory immune thrombocytopenia with romiplostim |
| Q91842424 | Systematic literature review of treatments used for adult immune thrombocytopenia in the second-line setting |
| Q33436422 | TPO-RAs in pITP: description of a case series and analysis of predictive factors for response |
| Q33407279 | The efficacy and safety of romiplostim in adult patients with chronic immune thrombocytopenia |
| Q33417700 | The pharmacology and clinical application of thrombopoietin receptor agonists |
| Q96304947 | The role of romiplostim for pediatric patients with immune thrombocytopenia |
| Q33414420 | The treatment for primary immune thrombocytopenia with romiplostim in adult and paediatric patients: use experience at a Spanish university hospital |
| Q31089024 | Thrombopoietin Receptor Agonist Use in Children: Data From the Pediatric ITP Consortium of North America ICON2 Study |
| Q47305608 | Thrombopoietin receptor agonists (TPO-RAs) in patients with persistent or chronic immune thrombocytopenia (ITP). |
| Q91898972 | Thrombopoietin receptor agonists: ten years later |
| Q92686510 | Treatment efficacy for adult persistent immune thrombocytopenia: a systematic review and network meta-analysis |
Search more.